http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115148364-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f4028822c87c88b2f84b76ddf3918059 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B20-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B30-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B20-50 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H50-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B30-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B20-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B20-20 |
| filingDate | 2022-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_88b2f36a0e2ba0b21c281adcd34d9a71 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55b83402c5509223d8e9d7ad11c7bd0b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0044e5a9b723d813ca1551dc9f649ad8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cce7b6e5e6892282f97db963a6938bfb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25b3dc5311af9cae9e085548c3571675 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b33e16bd9d9e517bc14e47de03747a2d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d78e6a9039a32c6de3cc12f8a89b6b78 |
| publicationDate | 2022-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-115148364-A |
| titleOfInvention | Device and computer-readable storage medium for predicting prognosis of DLBCL-naïve patients based on peripheral blood ctDNA levels |
| abstract | The invention discloses a device and a computer-readable storage medium for predicting the prognosis of newly treated DLBCL patients based on the level of peripheral blood ctDNA in the field of diagnosis. The invention adopts the NGS method of targeted region to detect the mutation of 188 genes closely related to lymphoma in peripheral blood ctDNA of DLBCL patients after receiving first-line standard treatment for 2 cycles, calculates the content of plasma ctDNA, and finds that the ctDNA after 2 cycles of treatment Plasma ctDNA content was significantly correlated with the clinical prognosis of patients. According to the level of ctDNA content, the present invention can perform prognosis stratification of patients, establishes a non-invasive, simple and easy device for predicting the prognosis of newly treated patients with DLBCL, and can identify patients who may not benefit from first-line chemotherapy in the early stage of treatment. Patients, provide reference information for clinicians to adjust treatment plans, and help promote the development of individualized treatment of malignant lymphoma. |
| priorityDate | 2022-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 27.